# Modular Trial of sEphB4-HSA in EphrinB2-High Solid Tumors

> **NCT06493552** · PHASE2,PHASE3 · RECRUITING · sponsor: **Vasgene Therapeutics, Inc** · enrollment: 700 (estimated)

## Conditions studied

- Muscle-Invasive Bladder Carcinoma
- Metastatic Urothelial Carcinoma

## Interventions

- **DRUG:** SEphB4-HSA
- **DRUG:** Pembrolizumab
- **DRUG:** Gemcitabine
- **DRUG:** Cisplatin
- **DRUG:** Enfortumab vedotin

## Key facts

- **NCT ID:** NCT06493552
- **Lead sponsor:** Vasgene Therapeutics, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-03-15
- **Primary completion:** 2029-09
- **Final completion:** 2034-08
- **Target enrollment:** 700 (ESTIMATED)
- **Last updated:** 2025-04-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06493552

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06493552, "Modular Trial of sEphB4-HSA in EphrinB2-High Solid Tumors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06493552. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*